Skip to main content
micro-community-banner
 
  • Saved

made a Post

hsa-MicroRNA-28-5p Inhibits Diffuse Large B-Cell Lymphoma Cell Proliferation by Downregulating 14-3-3ζ Expression

MicroRNAs (miRNAs) participate in the comprehensive biological process of several cancer types. In our former study, we found that hsa-microRNA- (miR-)28-5p was downregulated, but tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activating protein zeta ..... see more

Source : https://www.hindawi.com/journals/ecam/2022/4605329/



Conclusion/Relevance: “Our goal was to reveal the role of hsa-miR-28-5p in DLBCL …. Western blotting, and qRT-PCR verified that hsa-miR-28-5p negatively regulated YWHAZ expression by directly targeting its 3' untranslated regions in DLBCL cells. hsa-miR-28-5p may suppress the growth of DLBCL cells by inhibiting YWHAZ expression. These...

  • Saved

made a Post

Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study - PubMed

In this Asian population-based cohort, we found that incident CVDs can occur soon after DLBCL treatment and continued to occur throughout survivorship. Clinicians are advised to balance the risks and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35026723/



Conclusions: In this Asian population-based cohort, we found that incident CVDs can occur soon after DLBCL treatment and continued to occur throughout survivorship. Clinicians are advised to balance the risks and benefits of treatment choices to minimize the risk of CVD.

  • Saved

made a Post

Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study - PubMed

doi: 10.4143/crt.2021.1168. Online ahead of print. 1 Department of Hematology-Oncology, Ajou University Hospital, Suwon, Korea. 2 Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34990525/


Conclusion: Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

  • Saved

made a Post

An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo

WK500B exhibits potent efficacy against DLBCL in vitro and in vivo. * WK500B shows favourable pharmacokinetic and presents superior druggability. * WK500B could be a promising therapeutic drug candidate for ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S0304383521006583?via=ihub


Conclusion/Relevance: WK500B is a promising candidate that could be developed as an effective orally available therapeutic agent for DLBCL.

  • Saved

made a Post

Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of large lymphoid B cell malignancy with distinct clinical and genetic features. Recently, NOTCH1 mutations were identified in DLBCL cases by ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fonc.2021.746577/full



Conclusion/Relevance: In conclusion, DLBCL patients with the NOTCH1 mutations have worse PFS and OS, and the NOTCH1 mutations can be used as an independent predictor for patients with DLBCL.

  • Saved

made a Post

Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma - PubMed

doi: 10.1080/10428194.2021.2020782. Online ahead of print. 1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Translational Molecular Pathology, The ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34969327/



Conclusion/Relevance: The beneficial effect of statins on the anti-lymphoma activity of the rituximab-based chemotherapy regimen is controversial. Here, we retrospectively reviewed patients with naïve-treated advanced diffuse large B-cell lymphoma (DLBCL) receiving frontline R-CHOP, and for whom data regarding differential statins use was...

  • Saved

made a Post

Construction and validation of a risk scoring model for diffuse large B-cell lymphoma based on ferroptosis-related genes and its association with immune infiltration - PubMed

doi: 10.1016/j.tranon.2021.101314. Online ahead of print. 1 Departments of Hematology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong 528300, China. Electronic address: [email protected] 2 Department ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34920339/


Conclusions: In this study, a ferroptosis-based risk scoring model for patients with DLBCL was constructed and validated in an independent dataset. This risk score model has a better efficacy in predicting survival compared to clinical characteristics.

  • Saved

made a Post

Double-hit lymphoma: optimizing therapy - PubMed

Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34889402/


Conclusion/Relevance: Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some cases have high-grade morphology and frequently harbor MYC and BCL2 and/or BCL6...

  • Saved

made a Post

DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway

DCZ0014 inhibits cell proliferation by inducing apoptosis and cell cycle arrest. * Lyn/Syk in the B cell receptor signaling pathway are regulated in DCZ0014-induced apoptosis. * DCZ0014 inhibits tumor growth ..... see more

Source : https://www.sciencedirect.com/science/article/pii/S1476558621001056?via=ihub


Conclusion/Relevance: Tumor xenograft model showed that DCZ0014 not only inhibited tumor growth but also extended the survival time of mice. Thus, DCZ0014 showed potential for clinical application in the treatment of patients with DLBCL.

  • Saved

made a Post

Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma

ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy arising from germinal center or post-germinal center B-cells that retain many of the properties of normal B-cells. Here we show ..... see more

Source : https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.2003533


Conclusion/Relevance: In this work, we demonstrate that (1) the expression of IL-10 and IL-10R is a hallmark of DLBCL and strongly correlated with STAT3 phosphorylation and with MYD88/BCR mutations in DLBCL cell lines and DLBCL patients, that (2) IL-10 signaling is cell-intrinsically required for DLBCL growth in ectopic and orthotopic...

  • Saved

made a Post

Prognostic implications of tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B‐cell lymphoma in the North Indian population

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between ..... see more

Source : https://onlinelibrary.wiley.com/doi/10.1111/apm.13195


Conclusion: TME plays significant role in the prognosis of PCNS-DLBCL. Increased number of CD4 T cells and PD-L1 expressing immune cells are associated with better prognosis in PCNS-DLBCL. Further studies with larger sample size are required to evaluate the role of targeted therapy against TME and immune check point inhibitors in this disease.

  • Saved

made a Post

Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England - PubMed

(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may be explained by patients' comorbidities. We aimed to assess the association between comorbidities and the survival of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34830964/


Conclusion/Relevance: Deprivation is consistently associated with poorer survival among patients diagnosed with DLBCL or FL, after adjusting for co/multimorbidities. Comorbidities and multimorbidities need to be considered when planning public health interventions targeting haematological malignancies in England.

  • Saved

made a Post

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in ..... see more

Source : https://www.mdpi.com/2072-6694/13/22/5827


Conclusion/Relevance: Immunotherapy has played a pivotal role in the management of relapsed DLBCL. Stem cell transplant and CAR T-cell therapy are curative treatment modalities for relapsed disease. Despite this, a subset of patients continues to progress, and their outcomes remain dismal. Newer therapeutic options to optimize outcomes as well...

  • Saved

made a Post

Primary high-grade diffuse large B-cell lymphoma of the glans penis - PubMed

Diffuse large B-cell lymphoma (DLBCL) of the penis is a rare haematological malignancy, with less than 30 cases being reported in the literature. Our case mentions a 57-year-old man who ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34772674/


Our case mentions a 57-year-old man who presented with a penile lesion that was diagnosed as DLBCL on histological biopsy. Targeted investigation and proper diagnosis are essential to distinguish it from squamous cell carcinoma (SCC) of the glans, which presents similarly.

  • Saved

made a Post

Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia - PubMed

Myeloproliferative neoplasia (MPN) and lymphoma are regarded as distinct diseases with different pathogeneses. However, patients that are diagnosed with both malignancies occur more frequently in the population than expected. This ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34771688/


These results imply an underlying disturbance of tumor molecular biology, and in turn an alternative pathogenesis for tumors in these patients with both myeloid and lymphoid malignancies.

  • Saved

made a Post

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell ..... see more

Source : https://www.nih.gov/news-events/news-releases/ibrutinib-improves-survival-younger-people-diffuse-large-b-cell-lymphoma

  • Saved

made a Post

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL - PubMed

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34739844/

  • Saved

made a Post

Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry - PubMed

Although diffuse large B-cell lymphoma (DLBCL) occasionally lacks surface immunoglobulin light chain restriction (iLCR) on flow cytometry (FCM), little evidence is available for iLCR-negative DLBCL. We retrospectively compared clinicopathological features ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34707034/

  • Saved

made a Post

Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial - PubMed

doi: 10.1007/s00432-021-03796-z. Online ahead of print. 1 Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstraße 55, 45147 Essen, Germany. [email protected] 2 Zentrallabor, Universitätsklinikum Essen, Essen, Germany. [email protected] 3 Klinik für Nuklearmedizin, Universitätsklinikum ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34708297/

  • Saved

made a Post

Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma - PubMed

Diffuse large B-cell lymphoma (DLBCL) is a common lymphoproliferative and invasive disease. The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34586105/